Ratings Ambu A/S

Equities

AMBU B

DK0060946788

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:42 2024-05-08 am EDT			5-day change	1st Jan Change
119.6 ^DKK	-0.46%		+5.80%	+13.64%

Apr. 12	Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest	DJ
Apr. 11	U.S. Futures Down, European Stocks Mixed	DJ

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company's profit outlook over the next few years is a strong asset.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 77.68 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
AMBU A/S	+13.64%	4.6B	B
ABBOTT LABORATORIES	-4.84%	182B	C+
MEDTRONIC PLC	+0.56%	110B	C
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B	A
DEXCOM, INC.	+2.39%	50.53B	B-
CENCORA, INC.	+9.36%	44.8B	B-
HOYA CORPORATION	+2.70%	40.7B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	32.3B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B	A-
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes